Walter S. Woltosz Sells 20,000 Shares of Simulations Plus, Inc. (NASDAQ:SLP) Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the sale, the director now directly owns 3,402,584 shares in the company, valued at $115,381,623.44. The trade was a 0.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Simulations Plus Stock Performance

Simulations Plus stock opened at $35.58 on Friday. The stock has a market cap of $714.80 million, a P/E ratio of 88.95 and a beta of 0.82. Simulations Plus, Inc. has a fifty-two week low of $24.00 and a fifty-two week high of $51.22. The firm’s fifty day moving average price is $30.65 and its 200-day moving average price is $32.45.

Analyst Upgrades and Downgrades

SLP has been the topic of a number of analyst reports. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp boosted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, January 24th. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. BTIG Research lowered their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Finally, Stephens began coverage on shares of Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Simulations Plus presently has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. increased its stake in Simulations Plus by 82.6% in the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after acquiring an additional 370 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Simulations Plus by 53.6% in the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after acquiring an additional 427 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Simulations Plus by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after acquiring an additional 456 shares during the last quarter. Pitcairn Co. increased its stake in Simulations Plus by 9.1% in the third quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock valued at $211,000 after acquiring an additional 549 shares during the last quarter. Finally, US Bancorp DE increased its stake in Simulations Plus by 14.3% in the fourth quarter. US Bancorp DE now owns 5,687 shares of the technology company’s stock valued at $159,000 after acquiring an additional 713 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.